Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Personnel Moves Signal Continuity Under Commissioner Crawford

Executive Summary

Five top-level FDA personnel appointments implemented July 29 suggest general agency policy will likely go unchanged in the near future

You may also be interested in...



BIO exec heads to FDA

BIO Federal Government Relations Director David Boyer will join FDA as assistant commissioner for legislation March 20. The post was vacated by Patrick Ronan in July when he became chief of staff to then newly confirmed Commissioner Lester Crawford (1"The Pink Sheet" Aug. 1, 2005, p. 3). Boyer's background mirrors Ronan's who also served as BIO government relations director prior to joining FDA. Contrasted with Ronan, who had worked for the House Commerce Committee, Boyer's resume includes senior positions at HHS, most recently as special assistant for oversight in the office of the Assistant Secretary for Legislation...

BIO exec heads to FDA

BIO Federal Government Relations Director David Boyer will join FDA as assistant commissioner for legislation March 20. The post was vacated by Patrick Ronan in July when he became chief of staff to then newly confirmed Commissioner Lester Crawford (1"The Pink Sheet" Aug. 1, 2005, p. 3). Boyer's background mirrors Ronan's who also served as BIO government relations director prior to joining FDA. Contrasted with Ronan, who had worked for the House Commerce Committee, Boyer's resume includes senior positions at HHS, most recently as special assistant for oversight in the office of the Assistant Secretary for Legislation...

COX-2 Backlash? Fewer First-Cycle Approvals Would Signal Tougher FDA

A first-cycle drug approval rate significantly lower than 40% could provide the first sign of an effect of COX-2 inhibitor safety issues on FDA reviews, a report from the contract research organization Parexel states

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel